Januari 2012
29
6
Referentielijst
Albrecht J, Garbade SF, and Burgard P. 2009. Neuropsychological speed tests and blood
phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci Biobehav Rev
33:414-421.
Anjema K, Venema G, Hofstede FC, Carbasius Weber EC, Bosch AM, ter Horst NM, Hollak CEM,
Jonkers CF, Rubio-Gozalbo ME, van der ploeg EMC, de Vries MC, Janssen-Regelink RG, Janssen
MCH, Zweer-van Essen H, Boelen CCA, van der Herberg-van de Wetering NAP, Heiner-Fokkema
MR, van Rijn M, and van Spronsen FJ. 2011. The 48-hour tetrahydrobiopterin loading test in
patients with phenylketonuria:
Evaluation of protocol and influence of baseline phenylalanine concentration. Molecular Genetics
and Metabolism 104 (2011) S60-S63.
Blau N, Belanger-Quintana A, Demirkol M, Feillet F, Giovannini M, Macdonald A, Trefz FK, and van
Spronsen FJ. 2009. Optimizing the use of sapropterin (BH(4)) in the management of
phenylketonuria. Mol Genet Metab 96:158-163.
Blau N, van Spronsen FJ, and Levy HL. 2010. Phenylketonuria. Lancet 376:1417-1427.
Bosch AM, Tybout W, van Spronsen FJ, de Valk HW, Wijburg FA, and Grootenhuis MA. 2007. The
course of life and quality of life of early and continuously treated Dutch patients with
phenylketonuria. J Inherit Metab Dis 30:29-34.
Burgard P. 2000. Development of intelligence in early treated phenylketonuria. Eur J Pediatr 159
Suppl 2:S74-S79.
Burgard P, Armbruster M, Schmidt E, and Rupp A. 1994. Psychopathology of patients treated early
for phenylketonuria: results of the German collaborative study of phenylketonuria. Acta Paediatr
Suppl 407:108-110.
Burton BK, Nowacka M, Hennermann JB, Lipson M, Grange DK, Chakrapani A, Trefz F, Dorenbaum
A, Imperiale M, Kim SS, and Fernhoff PM. 2011. Safety of extended treatment with sapropterin
dihydrochloride in patients with phenylketonuria: results of a phase 3b study. Mol Genet Metab
103:315-322.
Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, Julio CR, van RM, Ahring K,
Belanger-Quintana A, and Macdonald A. 2011. Optimising growth in phenylketonuria: Current state
of the clinical evidence base. Clin Nutr.
Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, Thony B, and Blau N. 2004.
Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet
Metab 81:45-51.
Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, and Sergeant JA. 2002a. Short-term
dietary interventions in children and adolescents with treated phenylketonuria: effects on
neuropsychological outcome of a well-controlled population. J Inherit Metab Dis 25:419-430.
Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, and Sergeant JA. 2002b.
Sustained attention and inhibition of cognitive interference in treated phenylketonuria:
associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 40:7-
15.